Micro Hospitals
Market Cap
₹1,724 ₹1,724 Cr.
P/E
48.16
PEG
2.02
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis is validated by timely centre commissioning, improving utilization and continued adoption of specialized diagnostics and genomics.

The bull path requires earlier centre commissioning and stronger genomics adoption, while the bear path follows delayed commissioning, weaker utilization and lower realization.

Key Ratios

Debt to Equity
Debt to Equity
0.01
Div Yield (%)
Div Yield (%)
0.15
Individual < 2 lac
Individual < 2 lac
10.22 %
Institutions
Institutions
36.70 %
Market cap
Market cap
1,724 Cr
No. of Shareholders
No. of Shareholders
64,866
OPM (%)
OPM (%)
31.37 %
PE
PE
48.16
Prom Holding
Prom Holding
49.10 %
ROCE (%)
ROCE (%)
14.90
ROE (%)
ROE (%)
13.15
Sales
Sales
325 Cr
  • Suraksha Diagnostic
  • Dr. Lal Pathlabs
  • Metropolis Health.
  • TJI Diagnostic Chains
Last updated on 28 Sep 2026
  • Suraksha Diagnostic runs a hub-and-spoke diagnostics network. It offers laboratory testing, medical imaging and doctor consultations.
  • About 91% of revenue comes directly from patients.
  • Profit comes from laboratory testing and medical imaging. New centres earn far less until they mature.
  • Its lab is accredited by the College of American Pathologists. Per management, it is the largest organised chain in East India with 40% repeat business.
  • It is adding hubs and spokes in new territories. It is scaling genomics and advanced imaging. The ₹70–80Cr programme is large against ~₹310Cr revenue.
  • The latest quarter's 36% EBITDA margin includes a large lease-accounting increase. On the old basis the margin was 28.3%.
  • Receivables remain elevated after growing faster than revenue last year. Cash collection remains a pressure point.
  • FY27 hinges on new centres maturing and genomics scaling. Management guides 15% FY27 revenue growth and margin of at least 34%, up from 33%.
  • It still depends on West Bengal for about 95.5% of FY26 revenue. The shift to neighbouring states is still early.
  • Subsidiary dispute in Meghalaya was 21 Aug 2026; no update since
    ₹3.94Cr of investments, loans and receivables are under review against a ₹0.81Cr provision.
  • Growth and margin guide check early-mid Nov 2026
    The print shows if revenue tracks 15% growth and margin stays above 34% on the same basis.
  • Hub-and-spoke expansion programme FY27
    The ₹70–80Cr build adds 3 hubs and 6 spokes launched plus 4 hubs and 7 spokes upcoming toward 100 centres.
  • New centre ramp FY27
    27 new centres earn 6.5% margin against 40.9% for 45 mature centres. Maturation decides margin dilution.
  • Genomics scale-up FY27 exit
    Q1 revenue was ₹1.37Cr at 15-20% margin against an exit guide of about ₹4Cr a year.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
224
52W Range
High
360
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

3 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Customer Segment

Operational Metrics

    Select a Metric
    • Realization per Test (Rs)
    • Realization/Patient - Diagnostic Centres (Rs/Patient)
    • Number of Daily Patients - Diagnostic Centres (Ths)
    • Operating Margin/Test - Diagnostic Centres (Rs/Test)
    • No of Tests - Quarterly (Mn)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Suraksha Diagnostic Ltd. Business

    Suraksha Diagnostic offers one-stop integrated solutions for pathology and radiology testing and medical consultation services including X-rays, ultrasonography, computerized tomography, magnetic resonance imaging scans and vaccination services. In addition to integrated pathology and radiology testing services, it also offers omnichannel medical consultation services via online and offline modes to its customers.

    Suraksha Diagnostic major competitors are Dr. Lal Pathlabs, Metropolis Health., Thyrocare Tech., Vijaya Diagnostic.
    Market Cap of Suraksha Diagnostic is ₹1,824 Crs.
    While the median market cap of its peers are ₹12,937 Crs.

    Suraksha Diagnostic seems to be less financially stable compared to its competitors.
    Altman Z score of Suraksha Diagnostic is 7.23 and is ranked 5 out of its 5 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Feb May Aug May Aug Nov Sep Dec
    Investor Presentation Feb May Aug May Aug Nov Sep Dec
    Conference Call Feb May Aug Mar Jun Nov Sep Dec
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material